C12N 2840/10
Regulates levels of translation
Official title: regulates levels of translation
C12N2840/10 (Regulates levels of translation) appears on 167 US grants and 238 published applications in this corpus.
Search patents in C12N- Granted patents
- 167
- Published applications
- 238
- Assignees
- 160
- Inventors
- 498
- Latest grant
- 10 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 5 | 0 |
| 1997 | 9 | 0 |
| 1998 | 2 | 0 |
| 1999 | 7 | 0 |
| 2000 | 2 | 0 |
| 2001 | 4 | 1 |
| 2002 | 0 | 2 |
| 2003 | 3 | 6 |
| 2004 | 1 | 8 |
| 2005 | 4 | 4 |
| 2006 | 3 | 4 |
| 2007 | 2 | 4 |
| 2008 | 2 | 0 |
| 2009 | 2 | 5 |
| 2010 | 3 | 9 |
| 2011 | 4 | 11 |
| 2012 | 1 | 3 |
| 2013 | 5 | 13 |
| 2014 | 3 | 12 |
| 2015 | 12 | 13 |
| 2016 | 14 | 10 |
| 2017 | 10 | 13 |
| 2018 | 9 | 17 |
| 2019 | 4 | 17 |
| 2020 | 9 | 11 |
| 2021 | 10 | 19 |
| 2022 | 9 | 9 |
| 2023 | 8 | 8 |
| 2024 | 9 | 13 |
| 2025 | 6 | 14 |
| 2026 | 2 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Biosensors for detecting and/or neutralizing bioavailable uranium and related U-sensitive genetic molecular components, gene cassettes, vectors, genetic circuits, compositions, methods and systems10 Mar 2026US 12,571,058 B2Lawrence Livermore National Security, LLC
- GM3 synthase vectors and uses thereof17 Feb 2026US 12,553,036 B2The Clinic for Special Children, Inc.
- Gene therapy for neurodegenerative disorders9 Dec 2025US 12,491,267 B2The Brigham and Women S Hospital, Inc.
- RNA cleavage-induced transcript stabilizer and uses thereof25 Nov 2025US 12,480,119 B2Massachusetts Institute of Technology
- Artificial nucleic acid molecules for improved protein or peptide expression4 Nov 2025US 12,460,204 B2CureVac AG
- Multi-terminus polya polynucleotides20 Aug 2026US 2026/0241034 A1
- Viral vector carrying smn gene expression cassette and use thereof13 Aug 2026US 2026/0234668 A1Genecombio Ltd.
- Artificial polynucleotide molecules for enhanced stability and translation6 Aug 2026US 2026/0226129 A1
- Utr for improving translation efficiency and/or stability of rna molecule and use thereof23 Jul 2026US 2026/0209719 A1Shenzhen Shenxin Biotechnology Co., Ltd.
- Gm3 synthase vectors and uses thereof23 Jul 2026US 2026/0209721 A1The Clinic for Special Children, Inc.
Most cited
By later US patents
- Genetic constructs for delaying or repressing the expression of a target gene369US 6,573,099 B2Benitec Australia Limited · 2003
- Preparation of functional human factor VIII in mammalian cells using methotrexate based selection276US 4,965,199 AGenentech, Inc. · 1990
- Isolation of novel AAV'S and uses thereof107US 9,217,155 B2University of Massachusetts · 2015
- Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein68US 9,447,431 B2CureVac AG · 2016
- Isolation of novel AAV's and uses thereof63US 9,596,835 B2University of Massachusetts · 2017